SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline

Bellwether Of Post-COVID Sentiment

 
• By Jung Won Shin

SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.

Dollar bills
SK’s Successful IPO To Speed Up Offerings By Other Biotechs

More from South Korea

More from Focus On Asia